ECOR vs STIM

For growth investors, Neuronetics, Inc.

(STIM) is the stronger pick with 99. 2% revenue growth year-over-year, versus 27. 2% for electroCore, Inc. (ECOR). Analysts rate Neuronetics, Inc. (STIM) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, electroCore, Inc.

(ECOR) delivered a total return of -72. 1%, compared to -86. 7% for Neuronetics, Inc. (STIM). Over 10 years, the gap is even starker: STIM returned -93. 4% versus ECOR's -97. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Neuronetics, Inc.

(STIM) is the lower-risk stock at 1. 90β versus electroCore, Inc. 's 2. 06β — meaning ECOR is approximately 9% more volatile than STIM relative to the S&P 500.

By revenue growth (latest reported year), Neuronetics, Inc.

(STIM) is pulling ahead at 99. 2% versus 27. 2% for electroCore, Inc. (ECOR). On earnings-per-share growth, the picture is similar: Neuronetics, Inc. grew EPS 57. 2% year-over-year, compared to -3. 8% for electroCore, Inc.. Over a 3-year CAGR, ECOR leads at 55. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Neuronetics, Inc.

(STIM) is the more profitable company, earning -26. 1% net margin versus -43. 6% for electroCore, Inc. — meaning it keeps -26. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: STIM leads at -21. 1% versus -41. 1% for ECOR. At the gross margin level — before operating expenses — ECOR leads at 86. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Neuronetics, Inc.

(STIM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. electroCore, Inc. (ECOR) carries a higher beta of 2. 06 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (STIM: -93. 4%, ECOR: -97. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.